Journal of Hematology and Oncology Research

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Hematology and Oncology Research-Targeted therapies-Cesar A. Perez

united states

James Graham Brown Cancer Center
University of Louisville

Send an Email

Cesar A. Perez


529 S Jackson St, Suite 426
Louisville, KY 40202
United States

Research Interests:

Targeted therapies, Malignant Hematology, Lymphomas, Multiple Myeloma, Head and Neck Cancer, Lung Cancer, Refractory Thyroid Cancer, Multi-kinase inhibitors.


  • Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck.  Perez CA, Song H, Raez LE, Agulnik M., Dekker A, Stenson K., Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE.  Oral Oncol. 2012 Apr 16. PMID: 22513208
  • Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Perez CA, Velez M, Raez LE, Santos ES.  Lung Cancer. 2014 May;84(2):110-115. PMID: 24598368
  • Hodgkin Lymphoma in Pregnancy: Achieving the Best Outcome for Both Mother and Infant. Van Driessche F, Perez CA, Clin Adv Hematol Oncol 2013. 11(8): 537-8.  PMID: 24518428
  • Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.  Westin GF,  Perez CA, Wang E,  Glück S. Int J Biol Markers. 2013 Aug 29;28(3):233-241.  PMID: 23999849
  • Targeting the c-Met pathway in lung Cancer.  Belalcazar A; Azana D, Perez, CA; Raez LE, Santos ES.  Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. PMID: 22500688